Free Trial
NASDAQ:JAGX

Jaguar Animal Health Q2 2026 Earnings Results & Report

Jaguar Animal Health logo
$0.42 0.00 (0.00%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$0.40 -0.02 (-4.73%)
As of 09:09 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Jaguar Animal Health beat analyst earnings expectations but missed on revenue in its Q2 2026 results, released August 19, 2026. The company reported EPS of -$15.70 versus the -$782.25 consensus estimate, while revenue of $1.23 million fell short of the $4.24 million estimate by $3.02 million.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
After Market Closes
Conference Call
7:00 AM ET

Jaguar Animal Health EPS Results

Actual EPS
-$15.70
Consensus EPS
-$782.25
Beat/Miss
Beat by +$766.55
One Year Ago EPS
N/A

Jaguar Animal Health Revenue Results

Actual Revenue
$1.23 million
Expected Revenue
$4.24 million
Beat/Miss
Missed by -$3.02 million
YoY Revenue Growth
N/A

Upcoming Earnings

Jaguar Animal Health's Q3 2026 earnings is estimated for Monday, November 16, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 17, 2026 at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Jaguar Animal Health Q2 2026 Earnings FAQ

Jaguar Animal Health (NASDAQ:JAGX) reported earnings of -$15.70 per share for Q2 2026, beating the consensus estimate of -$782.25. The report was announced on Wednesday, August 19, 2026.

Jaguar Animal Health reported revenue of $1.23 million for Q2 2026, against a consensus estimate of $4.24 million.

Jaguar Animal Health's next earnings date is estimated for Monday, November 16, 2026. MarketBeat tracks confirmed and estimated earnings dates for Jaguar Animal Health on the company's earnings history page.

Jaguar Animal Health Earnings Headlines

Every Starlink dish pays this stock
There's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.tc pixel
Jaguar Health, Inc.(BOIN:) dropped from S&P TMI Index
See More Jaguar Animal Health Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Jaguar Animal Health? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Jaguar Animal Health and other key companies, straight to your email.

About Jaguar Animal Health

Jaguar Health, Inc., formerly Jaguar Animal Health (NASDAQ:JAGX), develops prescription medicines for gastrointestinal disorders in humans and animals. The company’s research has focused on plant-derived compounds, including crofelemer, which is derived from the Croton lechleri tree.

Jaguar’s animal-health product Canalevia-CA1 received FDA conditional approval for the treatment of chemotherapy-induced diarrhea in dogs. The company also develops and commercializes crofelemer-based medicines for human gastrointestinal conditions.

Jaguar expanded beyond its original animal-health focus through its 2017 merger with Napo Pharmaceuticals, a company developing plant-based medicines for human health. Napo became a Jaguar subsidiary, and the combined company adopted the Jaguar Health name.

View Jaguar Animal Health Profile